Gwendolyn Wu

Reporter

Gwendolyn is a reporter at BioPharma Dive covering biotech startups, venture capital and the ecosystem that supports them. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn co-directs the AAJA Young Professionals Network, and teaches at the California Scholastic Press Association summer workshop. She has degrees in history and sociology from the University of California at Santa Barbara.

Email [email protected]

Submit a tip to our team

118 articles by Gwendolyn Wu

Filter by month:

Novo Nordisk, Evotec partner in metabolic disease drug discovery pact
Sept. 26, 2023
Intarcia’s diabetes drug-device combo voted down again by FDA panel
Sept. 21, 2023
Genentech takes up a deal to make ‘molecular glue’ drugs
Sept. 20, 2023
Startup Airna emerges from stealth to bring RNA editing to a rare disease
Sept. 19, 2023
RayzeBio, Neumora price some of biotech’s largest IPOs this year
Sept. 14, 2023
Flagship-backed Generate raises $273M as its first drugs move to the clinic
Sept. 14, 2023
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’
Sept. 12, 2023
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
Sept. 6, 2023
Star Therapeutics adds another $90M to grow its galaxy of drug startups
Sept. 5, 2023
Intarcia, a former biotech unicorn, gets new life with startup deal
Aug. 30, 2023
Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt
Aug. 28, 2023
Neumora, a richly funded brain drug developer, readies for an IPO
Aug. 25, 2023
Radiopharmaceutical drugmaker RayzeBio signals plans to go public
Aug. 25, 2023
Foundery, a new biotech venture firm, sets out to speed early immune drug research
Aug. 22, 2023
In a year with few biotech IPOs, ‘crossover’ financings are hard to find
Aug. 16, 2023
Alltrna raises $109M for ‘transfer RNA’ drug vision
Aug. 9, 2023
Steve Jobs’ son raises $200M for cancer-focused venture fund
Aug. 2, 2023
Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows
July 28, 2023
European VC Medicxi raises $400M for ‘asset-centric’ biotech investing
July 27, 2023
Nexo allies with MD Anderson in pursuit of covalent cancer drugs
July 26, 2023
Editas names Biogen veteran as top scientist in latest executive change
July 24, 2023
Pfizer, Flagship join forces to hunt for 10 new drugs
July 18, 2023
Sanofi expands research deal with gene editing startup Scribe
July 17, 2023
Apogee, Sagimet price IPOs in positive sign for sluggish biotech market
July 14, 2023
Rupert Vessey, former Bristol Myers exec, to join Flagship as top scientist
July 13, 2023
‘It’s felt like Groundhog Day’: Biotech IPO slump drags on through 2023
July 6, 2023
F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn
June 30, 2023
Lilly to acquire cancer antibody drug startup Emergence
June 29, 2023
Startup Tagworks raises $65M to make ‘click-to-release’ cancer drugs
June 22, 2023
Flagship’s latest startup aims to take the guesswork out of small molecule drugs
June 21, 2023
Attovia, a new California biotech, launches with plans to rethink how drugs bind their targets
June 20, 2023
Cell and gene therapy manufacturing: the next generation of startups
June 20, 2023
Startup Eikon, led by Merck vets, buys drugs from three biotechs and banks another $106M
June 1, 2023
Atea rejects takeover bid from Concentra
May 30, 2023
Serial biotech founder Tim Springer on investing in startups and democratizing antibody research
May 26, 2023
Concentra bids on Atea, seeking to acquire another struggling biotech
May 23, 2023
ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs
May 23, 2023
Biotech Scribe strikes gene editing deal with Lilly subsidiary
May 16, 2023
Flagship’s newest startup is imitating nature to make new drugs
May 16, 2023
Nido debuts with $109M for its precision approach to brain drugs
May 15, 2023
FibroGen grabs an option to buy cancer drug startup Fortis
May 9, 2023
Recursion to acquire two Canadian drug discovery startups
May 8, 2023
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
May 4, 2023
Ovid partners with Waksal startup to develop drugs for rare brain disorders
May 1, 2023
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023
A startup taking a different approach to Alzheimer’s gets fresh funds, Lilly backing
April 27, 2023
Orbital raises $270 million in biotech’s largest Series A round this year
April 26, 2023
GV’s Cathy Friedman on optimism in biotech and the pitches that make her wary
April 18, 2023
A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab
April 5, 2023
New biotech investor Cure Ventures closes first fund, raising $350M
April 4, 2023
After an ‘amazing year,’ SR One raises $600M to fuel more drug startups
March 27, 2023
Biotech startups face ‘Series A cliff’ as venture capital stays cautious
March 24, 2023
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
March 22, 2023
With focus on fibrosis, startup Mediar draws big pharma backing
March 15, 2023
SVB’s failure was contained. Its effects on biotech could still linger.
March 14, 2023
Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’
March 14, 2023
Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug
March 9, 2023
Flagship’s latest startup emerges with a plan for ‘smarter biologics’
March 7, 2023
GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins
March 7, 2023
Amid industry turbulence, Chroma raises fresh funding to edit the epigenome
March 1, 2023
Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs
Feb. 21, 2023
With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem
Feb. 16, 2023
A new generation of biotech leaders is emerging. Can they change how drug startups are built?
Feb. 14, 2023
Another biotech IPO hits the market, as Mineralys raises $192M
Feb. 9, 2023
Magenta to explore sale, merger after study setback
Feb. 3, 2023
Biotech startup Structure pulls off rare IPO, raising $161M
Feb. 2, 2023
A startup launches with plans to open up a gene and cell therapy bottleneck
Jan. 31, 2023
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Jan. 24, 2023
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023
5 questions facing emerging biotech in 2023
Jan. 10, 2023
Sesen, Carisma merger plans draw shareholder opposition
Jan. 4, 2023
Belharra debuts with $130M in funding, Genentech partnership
Jan. 4, 2023
FDA halts planned trial of Entrada Duchenne drug
Dec. 20, 2022
A San Diego startup sees covalent biologics as the next frontier in cancer drugs
Dec. 15, 2022
Flagship’s Lovisa Afzelius on creating a successful biotech and a ‘very different’ startup market
Dec. 13, 2022
Dantari emerges with a new way to make cancer drug conjugates
Dec. 8, 2022
Star Therapeutics launches Vega, growing its galaxy of drug startups
Dec. 6, 2022
With $81M, Entact Bio takes a new approach to fixing helpful proteins
Dec. 6, 2022
Gene editing startup iECURE returns to investors for fresh funding
Nov. 30, 2022
CinCor shares dive after blood pressure drug fails key trial
Nov. 28, 2022
Cancer drugmaker Plexxikon gets new life as Opna Bio
Nov. 21, 2022
Former Rubius CEO to lead buzzy Flagship startup
Nov. 17, 2022
Jnana deepens ties with Roche and grabs a new round of funding
Nov. 15, 2022
After $250M Roche buyout, a startup plans a second strike with fresh funding
Nov. 15, 2022
Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug
Nov. 15, 2022
Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs
Nov. 15, 2022
Third Rock-backed Faze Medicines shutters two years after launch
Nov. 10, 2022
Artiva cancels IPO plans and cuts a deal with Affimed
Nov. 3, 2022
Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
Nov. 3, 2022
Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs
Nov. 1, 2022
An unusual alliance opens a gene and cell therapy hub outside Boston
Oct. 27, 2022
Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower’ and going from target to drug
Oct. 25, 2022
Prime Medicine raises $175M in one of the year’s largest biotech IPOs
Oct. 20, 2022
A startup plans an IPO to give a shelved Lilly drug another shot
Oct. 19, 2022
Treeline Bio deepens investor roots with fresh funding for cancer drug research
Oct. 17, 2022
Covalent drugs take the stage — again — in Atlas Venture’s latest startup
Oct. 14, 2022
Ascidian starts up with $50M and a twist on RNA editing
Oct. 12, 2022
Brain disease startup Neumora draws more funding for ambitious research plan
Oct. 11, 2022
New TYK2 inhibitors: a growing race to top Bristol Myers
Oct. 11, 2022
A Flagship startup secures $121M in new funding
Oct. 4, 2022
Incyte, branching out in dermatology, to buy startup Villaris
Oct. 3, 2022
Ventus sells its lead drug candidate to Novo Nordisk
Sept. 29, 2022
Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug
Sept. 28, 2022
Perlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’
Sept. 27, 2022
Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street
Sept. 21, 2022
Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch
Sept. 19, 2022
Acelyrin sets hopes high for arthritis drug with $300M fundraise
Sept. 14, 2022
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
Sept. 12, 2022
Mitochondrial drugs, with a twist: Pretzel Therapeutics launches with $72.5M in funding
Sept. 12, 2022
Beam-linked startup launches with an eye on the next generation of RNA drugs
Sept. 7, 2022
Drugging RNA with pills: small molecules for a big frontier
Sept. 6, 2022
Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech
Aug. 30, 2022
Bluejay raises $41M to bring hepatitis B drugs to clinical testing
Aug. 19, 2022
Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise
Aug. 16, 2022
Gemini’s fall gives Disc a way around biotech’s IPO slump
Aug. 10, 2022
A biotech startup gives Merck its next shot at treating Alzheimer’s
Aug. 9, 2022
How a small UK biotech ended up in Gilead’s hands
Aug. 5, 2022

Don't miss tomorrow's biopharma industry news

Gwendolyn Wu

Get in touch

118 articles by Gwendolyn Wu